Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Sage Therapeutics has decided to discontinue the development of a drug for Huntington's disease after disappointing results in Phase II trials. This comes after previous failures in studies for Parkinson's and Alzheimer's diseases. In other news, Novo Nordisk and Viking Therapeutics have presented promising data on GLP-1 therapies at AASLD 2024, potentially shaping the future of treatment for metabolic disorders. Pfizer has won a patent lawsuit against GSK in the UK regarding a respiratory syncytial virus vaccine, positioning both companies to compete in the global market.Additionally, controversial TV personality Dr. Oz has been chosen by Trump to head the agency overseeing Medicare and Medicaid. SignalChem Biotech offers kinase drug discovery solutions, supporting researchers with a wide range of services. This news update also covers Pfizer's executive changes, RFK Jr.'s nomination to HHS, and the challenges faced by rare disease players in funding research and development.